Tumour metabolomics in animal models of human cancer

Journal of Proteome Research

Volumn 6, Issue 2, 2007, Pages 498-505

  Griffin, Julian L ^a   Kauppinen, Risto A ^b  

^a UNIVERSITY OF CAMBRIDGE   (United Kingdom)

^b UNIVERSITY OF BIRMINGHAM   (United Kingdom)

Author keywords

Brain; Metabolomics; NMR spectroscopy; Pattern recognition; Tumor

Indexed keywords

BRAIN TUMOR; CANCER; CANCER DIAGNOSIS; CELL DEATH; CLINICAL ASSESSMENT; COLON CANCER; CONNECTIVE TISSUE TUMOR; CORRELATION ANALYSIS; HUMAN; IN VIVO STUDY; INFRARED SPECTROSCOPY; LIVER TUMOR; LYMPHOMA; MASS SPECTROMETRY; METABOLITE; METABOLOMICS; NONHUMAN; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY; PRIORITY JOURNAL; PROGNOSIS; PROSTATE CANCER; RAMAN SPECTROMETRY; REVIEW; TREATMENT RESPONSE; TUMOR CLASSIFICATION;

ANIMALS; BRAIN NEOPLASMS; COLONIC NEOPLASMS; DISEASE MODELS, ANIMAL; HUMANS; LIVER NEOPLASMS; LYMPHOMA; MALE; NEOPLASM PROTEINS; NEOPLASMS; NEOPLASMS, EXPERIMENTAL; PROSTATIC NEOPLASMS; SPECTROSCOPY, FOURIER TRANSFORM INFRARED; SPECTRUM ANALYSIS, RAMAN;

ANIMALIA;

EID: 33847370301     PISSN: 15353893     EISSN: None     Source Type: Journal    
DOI: 10.1021/pr060464h     Document Type: Review

References (84)

1. Nicholson, J. K.; Connelly, J.; Lindon, J. C.; Holmes, E. Metabonomics: A platform for studying drug toxicity and gene function. Nat. Rev. Drug Discovery 2002, 1, 153-161.
2. Holmes, E.; Antti, H. Chemometric contributions to the evolution of metabonomics: Mathematical solutions to characterising and interpreting complex biological NMR spectra. Analyst 2002, 127, 1549-1557.
3. Eriksson, L.; Antti, H.; Gottfries, J.; Holmes, E.; Johansson, E.; Lindgren, F.; Long, I.; Lundstedt, T.; Trygg, J.; Wold, S. Using chemometrics for navigating in the large data sets of genomics, proteomics, and metabonomics (gpm). Anal. Bioanal. Chem. 2004, 380, 419-429.
4. Griffin, J. L.; Shockcor, J. P. Metabolic profiles of cancer cells. Nat. Rev. Cancer 2004, 4, 551-561.
5. 1H NMR visible lipids in the life and death of cells. Trends Biochem. Sci. 2000, 25, 357-362.
6. Oh, J.; Henry, R. G.; Pirzkall, A.; Lu, Y.; Li, X.; Catalaa, I.; Chang, S.; Dillon, W. P.; Nelson, S. J. Survival analysis in patients with glioblastoma multiforme: Predictive value of choline-to-N-acetylaspartate index, apparent diffusion coefficient, and relative cerebral blood volume. J. Magn. Reson. Imaging 2004, 19, 546-554.
7. 1H-NMR spectroscopy. NMR Biomed. 2002, 15, 37-44.
8. Gavva, S. R.; Wiethoff, A. J.; Zhao, P. Y.; Malloy, C. R.; Sherry, A. D. A C-13 isotopomer n.m.r. method for monitoring incomplete beta-oxidation of fatty acids in intact tissue. Biochem. J. 1994, 303, 847-853.
9. 31P nuclear magnetic resonance study. J. Neurochem. 1989, 53, 102-110.
10. 1H NMR spectroscopy at 4T: Application to schizophrenia. Magn. Reson. Mater. Phys., Biol. Med. 2005, 18, 276-282.
11. Mason, G. F.; Rothman, D. L.; Behar, K. L.; Shulman, R. G. NMR determination of the TCA cycle rate and alfa-ketoglutarate/glutamate exchange rate in rat brain. J. Cereb. Blood Flow Metab. 1992, 12, 434-447.
12. 1H magnetic resonance spectroscopy. Magn. Reson. Med. 1995, 33, 862-867.
13. Cheng, L. L.; Ma, M. J.; Becerra, L.; Ptak, T.; Tracey, I.; Lackner, A.; Gonzalez, R. G. Quantitative neuropathology by high resolution magic angle spinning proton magnetic resonance spectroscopy. Proc. Natl. Acad. Sci. U.S.A. 1997, 94, 6408-6413.
14. 1H NMR spectroscopy in vivo, ex vivo, and in vitro. J Biol. Chem. 2003, 278, 45915-45923.
15. Jellum, E.; Bjornson, I.; Nesbakken, R.; Johansson, E.; Wold, S. Classification of human cancer cells by means of capillary gas chromatography and pattern recognition analysis. J. Chromatogr. 1981, 217, 231-237.
16. Sugita, Y.; Yamada, S.; Sugita, S.; Sakata, K.; Morimatsu, M.; Shigemori, M. The biochemical analysis of neurotransmitters in central neurocytomas. Int. J. Mol. Med. 2001, 7, 521-525.
17. Olsen, P.; Rasmussen, M.; Zhu, W.; Tonnesen, E.; Stefano, G. B. Human gliomas contain morphine. Med. Sci. Monit. 2005, 11, MS18-21.
18. Bieberich, E.; Freischutz, B.; Suzuki, M.; Yu, R. K. Differential effects of glycolipid biosynthesis inhibitors on ceramide-induced cell death in neuroblastoma cells. J. Neurochem. 1999, 72, 1040-1049.
19. 1H MRS choline: Correlation with in vitro chemistry/histology. Life Sci. 1996, 58, 1929-1935.
20. Sullards, M. C.; Wang, E.; Peng, Q.; Merrill, A. H., Jr. Metabolomic profiling of sphingolipids in human glioma cell lines by liquid chromatography tandem mass spectrometry. Cell. Mol. Biol. 2003, 49, 789-797.
21. Brown, S. C.; Kruppa, G.; Dasseux, J. L. Metabolomics applications of FT-ICR mass spectrometry. Mass Spectrom. Rev. 2005, 24, 223-231.
22. Vaidyanathan, S.; Gaskell, S.; Goodacre, R. Matrix-suppressed laser desorption/ionisation mass spectrometry and its suitability for metabolome analyses. Rapid Commun. Mass Spectrom. 2006, 20, 1192-1198.
23. Diem, M.; Boydston-White, S.; Chiriboga, L. Infrared spectroscopy of cells and tissues: shining lights onto a novel subject. Appl. Spectrosc. 1999, 53, 148A-161A.
24. Boustany, N. N.; Crawford, J. M.; Manoharan, R.; Dasari, R. R.; Feld, M. S. Analysis of nucleotides and aromatic amino acids in normal and neoplastic colon mucosa by ultraviolet resonance raman spectroscopy. Lab. Invest. 1999, 79, 1201-1214.
25. Hanlon, E. B.; Manoharan, R.; Koo, T. W.; Shafer, K. E.; Motz, J. T.; Fitzmaurice, M.; Kramer, J. R.; Itzkan, I.; Dasari, R. R.; Feld, M. S. Prospects for in vivo Raman spectroscopy. Phys. Med. Biol. 2000, 45, R1-59.
26. Schultz, C. P.; Liu, K. Z.; J. B., J.; Mantsch, H. H. Prognosis of chronic lympocytic leukemia from infrared spectra of lymphocytes. J. Mol. Structr. 1997, 408, 253-256.
27. Bhakoo, K. K.; Williams, S. R.; Florian, C. L.; Land, H.; Noble, M. D. Immortalization and transformation are associated with specific alterations in choline metabolism. Cancer Res. 1996, 56, 4630-4635.
28. 1H NMR visible polyunsaturated fatty acids in BT4C gliomas undergoing canciclovir-thymidine kinase gene therapy -induced programmed cell death. Cancer Res. 2003, 63, 3195-3201.
29. 1H NMR spectroscopy reveals different responses in choline-containing metabolites upon gene therapy-induced programmed cell death in rat brain glioma. NMR Biomed. 2005, 18, 252-259.
30. Gillies, R. J.; Bhujwalla, Z. M.; Evelhoch, J.; Garwood, M.; Neeman, M.; Robinson, S. P.; Sotak, C. H.; Van Der Sanden, B. Applications of magnetic resonance in model systems: Tumor biology and physiology. Neoplasia 2000, 2, 139-151.
31. Gyngell, M. L.; Hoehn-Berlage, M.; Kloiber, O.; Michaelis, T.; Ernestus, R. I.; Horstermann, D.; Frahm, J. Localized proton NMR spectroscopy of experimental gliomas in rat brain in vivo. NMR Biomed. 1992, 5, 335-340.
32. Lahrech, H.; Zoula, S.; Farion, R.; Remy, C.; Decorps, M. In vivo measurement of the size of lipid droplets in an intracerebral glioma in the rat. Magn. Reson. Med. 2001, 45, 409-414.
33. 1H MRS detects polyunsaturated fatty acid accumulation during gene therapy of glioma: Implications for the in vivo detection of apoptosis. Nat. Med. 1999, 5, 1323-1327.
34. Lindskog, M.; Spenger, C.; Jarvet, J.; Graslund, A.; Kogner, P. Predicting resistance or response to chemotherapy by proton magnetic resonance spectroscopy in neuroblastoma. J. Natl. Cancer Inst. 2004, 96, 1457-1466.
35. Zoula, S.; Herigault, G.; Ziegler, A.; Farion, R.; Decorps, M.; Remy, C. Correlation between the occurrence of 1H-MRS lipid signal, necrosis and lipid droplets during C6 rat glioma development. NMR Biomed. 2003, 16, 199-212.
36. 1H NMR diffusion spectroscopy of BT4C rat glioma during thymidine kinase-mediated gene therapy in vivo: Identification of apoptotic response. Cancer Res. 1998, 58, 3791-3799.
37. Barba, I.; Cabanas, M. E.; Arus, C. The relationship between nuclear magnetic resonance-visible lipids, lipid droplets, and cell proliferation in cultured C6 cells. Cancer Res. 1999, 59, 1861-1868.
38. 1H magnetic resonance spectroscopic imaging: Comparison with maps of metabolites. Cancer Res. 2001, 61, 6524-6531.
39. Boros, L. G.; Lee, W. N.; Go, V. L. A metabolic hypothesis of cell growth and death in pancreatic cancer. Pancreas 2002, 24, 26-33.
40. Terpstra, M.; Gruetter, R.; High, W. B.; Mescher, M.; DelaBarre, L.; Merkle, H.; Garwood, M. Lactate turnover in rat glioma measured by in vivo nuclear magnetic resonance spectroscopy. Cancer Res. 1998, 58, 5083-5088.
41. 13C}-spectroscopy in rat glioma in vivo. J. Magn. Reson. 2005, 177, 129-138.
42. 31P NMR spectroscopic study of bioenergetic changes in radiation-induced fibrosarcoma-1 after radiation therapy. NMR Biomed. 1989, 2, 165-171.
43. 31P nuclear magnetic resonance spectroscopy. Cancer Res. 1988, 48, 4736-4742.
44. Mahmood, U.; Alfieri, A. A.; Ballon, D.; Traganos, F.; Koutcher, J. A. In vitro and in vivo P-31 nuclear magnetic resonance measurements of metabolic changes post radiation. Cancer Res. 1995, 55, 1248-1254.
45. 31P nuclear magnetic resonance with tumor growth in radioresistant and radiosensitive tumors. Radiat. Res. 1990, 121, 312-319.
46. Sijens, P. E.; Baldwin, N. J.; Ng, T. C. Multinuclear MR investigation of the metabolic response of the marine RIF-1 tumor to 5-fluorouracil chemotherapy. Magn. Reson. Med. 1991, 19, 373-385.
47. McSheehy, P. M.; Robinson, S. P.; Ojugo, A. S.; Aboagye, E. O.; Cannell, M. B.; Leach, M. O.; Judson, I. R.; Griffiths, J. R. Carbogen breathing increases 5-fluorouracil uptake and cytotoxicity in hypoxic murine RIF-1 tumors: A magnetic resonance study in vivo. Cancer Res. 1998, 58, 1185-1194.
48. Poptani, H.; Bansal, N.; Graham, R. A.; Mancuso, A.; Nelson, D. S.; Glickson, J. D. Detecting early response to cyclophosphamide treatment of RIF-1 tumors using selective multiple quantum spectroscopy (SelMQC) and dynamic contrast enhanced imaging. NMR Biomed. 2003, 16, 102-111.
49. 1H magnetic resonance spectroscopy. Neoplasia 2006, 8, 560-567.
50. 31P-NMR spectroscopy: In vivo monitoring of the local anti-tumor effects of systemic immune cell transfer. Int. J. Cancer 1996, 66, 484-495.
51. 31P magnetic resonance spectroscopy. Int. J. Radiat. Oncol. Biol. Phys. 1998, 41, 1157-1162.
52. 31P MRS. Magn. Reson. Med. 1998, 40, 411-420.
53. Anthony, M. L.; Zhao, M.; Brindle, K. M. Inhibition of phosphatidylcholine biosynthesis following induction of apoptosis in HL-60 cells. J Biol. Chem. 1999, 274, 19686-19692.
54. Blankenberg, F. G.; Storrs, R. W.; Naumovski, L.; Goralski, T.; Spielman, D. Detection of apoptotic cell death by proton nuclear magnetic resonance spectroscopy. Blood 1996, 87, 1951-1956.
55. 1H NMR spectra of a myeloma cell line correlates with the induced formation of cytoplasmic lipid droplets. Magn. Reson. Med. 1993, 29, 546-550.
56. 1H MRS-visible lipids accumulate during apoptosis of lymphoma cells in vitro and in vivo. Magn. Reson. Med. 2005, 54, 43-50.
57. 1H NMR detected proteins in the rat cerebral cortex in vivo and in vitro. NMR Biomed. 1993, 6, 242-246.
58. Griffiths, J. R.; McSheehy, P. M.; Robinson, S. P.; Troy, H.; Chung, Y. L.; Leek, R. D.; Williams, K. J.; Stratford, I. J.; Harris, A. L.; Stubbs, M. Metabolic changes detected by in vivo magnetic resonance studies of HEPA-1 wild-type tumors and tumors deficient in hypoxia-inducible factor-1beta (HIF-1beta): evidence of an anabolic role for the HIF-1 pathway. Cancer Res. 2002, 62, 688-695.
59. Griffiths, J. R.; Stubbs, M. Opportunities for studying cancer by metabolomics: Preliminary observations on tumors deficient in hypoxia-inducible factor 1. Adv. Enzyme Regul. 2003, 43, 67-76.
60. 1H MRS markers of tumour growth in intrasplenic tumours and liver metastasis induced by injection of HT-29 cells in nude mice spleen. NMR Biomed. 1998, 11, 93-106.
61. 1H-MRS in the DEN-induced hepatocellular carcinoma in Wistar rat. J. Cancer Res. Clin. Oncol. 2005, 131, 597-602.
62. Tesiram, Y. A.; Saunders, D.; Towner, R. A. Application of proton NMR spectroscopy in the study of lipid metabolites in a rat hepatocarcinogenesis model. Biochim. Biophys. Acta 2005, 1737, 61-68.
63. 1H MR visible lipids in colon tissue from normal and carcinogen-treated rats. NMR Biomed. 1995, 8, 33-40.
64. 31P-NMR studies of human colon cancer in-vitro and in-vivo. Surg. Oncol. 1993, 2, 7-18.
65. Muruganandham, M.; Koutcher, J. A.; Pizzorno, G.; He, Q. In vivo tumor lactate relaxation measurements by selective multiple-quantum-coherence (Sel-MQC) transfer. Magn. Reson. Med. 2004, 52, 902-906.
66. van Laarhoven, H. W.; Gambarota, G.; Lok, J.; Lammens, M.; Kamm, Y. L.; Wagener, T.; Punt, C. J.; van der Kogel, A. J.; Heerschap, A. Carbogen breathing differentially enhances blood plasma volume and 5-fluorouracil uptake in two murine colon tumor models with a distinct vascular structure. Neoplasia 2006, 8, 477-487.
67. Coakley, F. V.; Qayyum, A.; Kurhanewicz, J. Magnetic resonance imaging and spectroscopic imaging of prostate cancer. J. Urol. 2003, 170, S69-S75.
68. Kiessling, F.; Huber, P. E.; Grobholz, R.; Heilmann, M.; Meding, J.; Lichy, M. P.; Fink, C.; Krix, M.; Peschke, P.; Schlemmer, H. P. Dynamic magnetic resonance tomography and proton magnetic resonance spectroscopy of prostate cancers in rats treated by radiotherapy. Invest. Radiol. 2004, 39, 34-44.
69. Fricke, S. T.; Rodriguez, O.; Vanmeter, J.; Dettin, L. E.; Casimiro, M.; Chien, C. D.; Newell, T.; Johnson, K.; Ileva, L.; Ojeifo, J.; Johnson, M. D.; Albanese, C. In vivo magnetic resonance volumetric and spectroscopic analysis of mouse prostate cancer models. Prostate 2006, 66, 708-777.
70. 1H MR spectroscopy. Magn. Reson. Med. 2003, 50, 1134-1143.
71. 1H MR spectroscopy: A pilot study at 4 T. Radiology 2004, 233, 424-431.
72. Preul, M. C.; Caramanos, Z.; Collins, D. L.; Villemure, J. G.; Leblanc, R.; Olivier, A.; Pokrupa, R.; Arnold, D. L. Accurate, noninvasive diagnosis of human brain tumors by using proton magnetic resonance spectroscopy. Nat. Med. 1996, 2, 323-325.
73. 1H magnetic resoance spectroscopic metabolite phenotypes. NeuroReport 1996, 7, 1597-1600.
74. Nelson, S. J.; Cha, S. Imaging glioblastoma multiforme. Cancer J. 2003, 9, 134-145.
75. Shukla-Dave, A.; Poptani, H.; Loevner, L. A.; Mancuso, A.; Serrai, H.; Rosenthal, D. I.; Kilger, A. M.; Nelson, D. S.; Zakian, K. L.; Arias-Mendoza, F.; Rijpkema, M.; Koutcher, J. A.; Brown, T. R.; Heerschap, A.; Glickson, J. D. Prediction of treatment response of head and neck cancers with P-31 MR spectroscopy from pretreatment relative phosphomonoester levels. Acad. Radiol. 2002, 9, 688-694.
76. Arias-Mendoza, F.; Smith, M. R.; Brown, T. R. Predicting treatment response in non-Hodgkin's lymphoma from the pretreatment tumor content of phosphoethanolamine plus phosphocholine. Acad. Radiol. 2004, 11, 368-376.
77. 31P MR spectral alterations in human hepatic tumours. NMR Biomed. 1998, 11, 354-359.
78. Li, C. W.; Kuo, Y. C.; Chen, C. Y.; Kuo, Y. T.; Chiu, Y. Y.; She, F. O.; Liu, G. C. Quantification of choline compounds in human hepatic tumors by proton MR spectroscopy at 3 T. Magn. Reson. Med. 2005, 53, 770-776.
79. 1H MR spectroscopy and MR imaging: Clinicopathologic case-controlled study. Radiology 2001, 221, 380-390.
80. 1H MR spectroscopic imaging of human prostate cancer. J. Magn. Reson. Imaging 2004, 20, 279-287.
81. Ward, J. M.; Devor-Henneman, D. E. Mouse models of human familial cancer syndromes. Toxicol. Pathol. 2004, 32, 90-98.
82. Ardenkjaer-Larsen, J. H.; Fridlund, B.; Gram, A.; Hansson, G.; Hansson, L.; Lerche, M. H.; Servin, R.; Thaning, M.; Golman, K. Increase in signal-to-noise ratio of > 10,000 times in liquid-state NMR. Proc. Natl. Acad. Sci. U.S.A. 2003, 100, 10158-10163.
83. Boros, L. G.; Brackett, D. J.; Harrigan, G. G. Metabolic biomarker and kinase drug target discovery in cancer using stable isotope-based dynamic metabolic profiling (SIDMAP). Curr. Cancer Drug Targets 2003, 3, 445-453.
84. Chaurand, P.; Schwartz, S. A.; Reyzer, M. L.; Caprioli, R. M. Imaging mass spectrometry: Principles and potentials. Toxicol. Pathol. 2005, 33, 92-101.